James J. Burns & Company LLC bought a new stake in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 12,823 shares of the company’s stock, valued at approximately $158,000. James J. Burns & Company LLC owned approximately 0.08% of Global X Genomics & Biotechnology ETF as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also modified their holdings of the company. Money Concepts Capital Corp purchased a new stake in shares of Global X Genomics & Biotechnology ETF during the fourth quarter valued at approximately $25,000. OLD Mission Capital LLC acquired a new stake in shares of Global X Genomics & Biotechnology ETF during the fourth quarter valued at about $37,000. Advisor Group Holdings Inc. increased its position in shares of Global X Genomics & Biotechnology ETF by 26.9% during the fourth quarter. Advisor Group Holdings Inc. now owns 3,916 shares of the company’s stock worth $49,000 after acquiring an additional 831 shares during the last quarter. Rockefeller Capital Management L.P. lifted its stake in shares of Global X Genomics & Biotechnology ETF by 19.4% in the fourth quarter. Rockefeller Capital Management L.P. now owns 9,200 shares of the company’s stock worth $116,000 after acquiring an additional 1,493 shares in the last quarter. Finally, Beaumont Financial Advisors LLC purchased a new position in Global X Genomics & Biotechnology ETF in the fourth quarter valued at about $166,000. 56.95% of the stock is currently owned by hedge funds and other institutional investors.
Global X Genomics & Biotechnology ETF Stock Down 1.8 %
GNOM stock opened at $11.79 on Friday. The stock’s 50 day moving average is $12.58 and its two-hundred day moving average is $12.38. Global X Genomics & Biotechnology ETF has a 52-week low of $11.55 and a 52-week high of $16.75. The company has a market capitalization of $186.75 million, a PE ratio of -5.04 and a beta of 1.03.
About Global X Genomics & Biotechnology ETF
Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Global X Genomics & Biotechnology ETF, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Global X Genomics & Biotechnology ETF wasn’t on the list.
While Global X Genomics & Biotechnology ETF currently has a “hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s list of the 10 best stocks to own in 2023 and why they should be in your portfolio.
